New drug aims to stop debilitating nosebleeds in rare disease
NCT ID NCT07255846
Summary
This is the first human trial for a new drug called TER-1754, designed for people with hereditary hemorrhagic telangiectasia (HHT), a disorder that causes frequent, severe nosebleeds and other bleeding problems. The main goal is to find a safe dose and see if the drug can reduce bleeding and improve quality of life. The study will enroll 90 participants to test the drug's safety and how well it works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Innovative Hematology, Inc.
RECRUITINGIndianapolis, Indiana, 46260, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.